Dr. Maxwell Sauder
Dr. Maxwell Sauder is a board-certified dermatologist in Canada (FRCPC) and the United States (DABD) with additional fellowship training. He earned his Doctor of Medicine degree at McMaster University and completed a residency in dermatology at The University of Ottawa where he was the chief resident and received The D.C. Montgomery Resident Award for excellence in research. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School.
Dr. Sauder is currently an assistant professor in the division of dermatology at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he has a large general dermatology practice, is the director of the Pigmented Lesion Clinic and is the research director conducting clinical trials for new therapies of various dermatologic conditions.
He is an active member in various dermatology organizations. Within the Canadian Dermatology Association, he is a member of the Sun Awareness Working Group. He is the Secretary of the Dermatology Association of Ontario. He is the Treasurer of the Section of Dermatology within the Ontario Medical Association where he advocates for dermatologists, doctors and most importantly patients.
Saturday APR 9, 2022
What’s New in Type 2?
Type 2 Inflammation Is the Predominant Inflammatory pathway driving Atopic dermatitis, and its understanding in AD and other Dermatological conditions continues to evolve. There are novel concepts where research is progressing such as barrier function, microbiome and neuroimmune mechanisms of itch. The arrival of novel agents specifically targeting T2i was a breakthrough around five years ago. We can now understand the long-term impact of specifically targeting the T2i pathway. There are also new dermatological diseases beyond AD where we now know T2i is playing an important role in pathophysiology.
- Review research updates on barrier dysfunction and in the pathophysiology of AD
- Review latest data in long term control of moderate to severe AD
- Review Type 2 inflammation as a therapeutic target in dermatologic diseases outside of AD